Financing ·
Innate Pharma raises €30M in equity financing to extend cash runway through Q1 2028
IPHAInnate Pharma SA
Innate Pharma reported a net loss of €19.6 million for the first half of 2026 and announced two material post-period events. The company closed a strategic partnership with Sobi for lacutamab, receiving a $75 million upfront payment on September 16, 2026, which triggers the initiation of the TELLOMAK-3 Phase 3 study in cutaneous T-cell lymphoma. Additionally, Innate Pharma completed a €30 million equity financing via private placement of approximately 17.6 million shares at €1.70 per share on August 18, 2026. These proceeds extend the company's cash runway through Q1 2028. The firm also appointed Markus Jensen as Chief Medical Officer effective September 1, 2026. Innate Pharma is a clinical-stage biotechnology company developing immunotherapies and antibody-drug conjugates for cancer treatment.